GlassScriptPhysician profile
Robert Howard Stewart
NPI 1750423034
$651,061.39
in general payments reported to CMS, 2019-2025
35 companies · $121K in 2025
The $121K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85K · 2020: $79K · 2021: $91K · 2022: $64K · 2023: $138K · 2024: $74K · 2025: $121K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $246K · Consulting Fee: $37K · Travel and Lodging: $19K · Honoraria: $19K · Food and Beverage: $10K · Education: $96.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $246,495.00 |
| Consulting Fee | $36,750.00 |
| Travel and Lodging | $19,474.12 |
| Honoraria | $18,975.00 |
| Food and Beverage | $10,479.93 |
| Education | $96.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $345,123.06 | 2021-2025 | Vraylar |
| Allergan, INC. | $144,491.34 | 2019-2021 | |
| Axsome Therapeutics, INC. | $54,482.33 | 2022-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31,401.52 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $27,831.06 | 2019-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $26,981.04 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $11,944.20 | 2019-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $3,586.82 | 2022-2024 | Quviviq |
| Bausch Health US, LLC | $2,236.74 | 2019-2025 | Aplenzin, Wellbutrin |
| Alkermes, INC. | $462.95 | 2021-2025 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $456.05 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $305.97 | 2019-2024 | Spravato |
| Tris Pharma INC | $261.07 | 2022-2025 | Dyanavel Xr |
| Lundbeck LLC | $237.53 | 2019-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $202.81 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $159.87 | 2019-2024 | |
| Noven Therapeutics, LLC | $134.88 | 2023-2025 | Xelstrym, Secuado |
| Neurocrine Biosciences, INC. | $134.39 | 2019-2025 | Ingrezza |
| Adlon Therapeutics L.P. | $99.88 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $89.36 | 2023-2024 | Horizant, Horizant |
| Neuronetics, INC. | $77.29 | 2019 | |
| Corium, LLC | $50.74 | 2023-2024 | Azstarys |
| Arbor Pharmaceuticals, INC. | $36.07 | 2019-2021 | |
| Integra Lifesciences Corporation | $33.10 | 2025 | Integra, Integra Dermal Regeneration Template, Surgimend |
| Kerecis Limited | $29.34 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Almatica Pharma LLC | $29.03 | 2024-2025 | Loreev Xr |
| Shire North American Group INC | $28.54 | 2019 | |
| Eisai INC. | $27.84 | 2021 | |
| Supernus Pharmaceuticals, INC. | $25.62 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $23.32 | 2022 | |
| Novo Nordisk INC | $19.81 | 2023 | Wegovy |
| Organogenesis INC. | $17.96 | 2024 | |
| Neos Therapeutics, LP | $15.30 | 2023 | Adzenys Xr-Odt |
| Avanir Pharmaceuticals, INC. | $12.67 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.